Eng C, Mulligan L M, Smith D P, Healey C S, Frilling A, Raue F, Neumann H P, Ponder M A, Ponder B A
CRC Human Cancer Genetics Research Group, University of Cambridge, Addenbrooke's Hospital, UK.
Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7. doi: 10.1111/j.1365-2265.1995.tb01903.x.
Medullary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between true sporadic MTC and a new mutation familial case is important for future clinical management of both the patient and family. The susceptibility gene for MEN 2 is the RET proto-oncogene. Systematic analysis for germline mutations of the RET proto-oncogene was performed in a series of 67 patients with apparently sporadic MTC to determine whether they were true sporadic cases or unsuspected de novo MEN 2 cases.
Sixty-seven unselected patients with sporadic MTC were randomly ascertained from clinic patients from four centres. The diagnosis of MTC was confirmed by histopathology. Germline DNA was extracted from peripheral blood leucocytes or from paraffin-embedded tissue and subsequently used for polymerase chain reaction amplification.
Polymerase chain reaction based RET mutation analysis was performed by direct double-stranded cycle sequencing of exons 10, 11, 13 and 16, within which the majority of MEN2 mutations have been shown to occur.
In this series, there was one proven case of germline mutation in RET codon 620, which previously has been shown to be responsible for MEN 2, thus indicating heritable disease. No germline mutation in codon 918, typical of MEN 2B, was found.
A figure of 1.5% germline mutations in 67 apparently sporadic MTC is lower than the incidence of familial disease reported in previous series involving clinical and biochemical screening. The presence of a germline mutation in the RET proto-oncogene in a patient with MTC indicates heritable disease. The absence of germline RET exon 10, 11, 13 or 16 mutation appears to rule out MEN 2A to a high probability, although the presence of a familial form of MTC other than classical MEN 2A cannot be excluded conclusively.
甲状腺髓样癌(MTC)既可以散发性出现,也可发生于常染色体显性遗传的2型多发性内分泌腺瘤(MEN)综合征中。区分真正的散发性MTC和新突变的家族性病例对于患者及其家族未来的临床管理非常重要。MEN 2的易感基因是RET原癌基因。对67例明显为散发性MTC患者进行了RET原癌基因种系突变的系统分析,以确定他们是真正的散发性病例还是未被怀疑的新发MEN 2病例。
从四个中心的临床患者中随机选取67例未经选择的散发性MTC患者。MTC的诊断经组织病理学证实。从外周血白细胞或石蜡包埋组织中提取种系DNA,随后用于聚合酶链反应扩增。
通过对10、11、13和16号外显子进行直接双链循环测序,进行基于聚合酶链反应的RET突变分析,已表明大多数MEN2突变发生在这些外显子内。
在该系列中,有1例经证实的RET密码子620种系突变病例,此前已证明该突变与MEN 2有关,因此表明为遗传性疾病。未发现MEN 2B典型的918密码子种系突变。
67例明显为散发性MTC中1.5%的种系突变率低于先前涉及临床和生化筛查系列报道的家族性疾病发病率。MTC患者中RET原癌基因种系突变的存在表明为遗传性疾病。RET外显子10、11、13或16未发生种系突变似乎极有可能排除MEN 2A,尽管不能完全排除除经典MEN 2A以外的家族性MTC形式的存在。